Physician profile
Sterling N Ransone
NPI 1003873662
$1,221.31
in general payments reported to CMS, 2019-2025
21 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $186 · 2021: $96.73 · 2024: $84.96 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.02 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $273.47 | 2019-2025 | Farxiga, Airsupra |
| Antares Pharma, INC. | $225.25 | 2025 | Xyosted |
| Pfizer INC. | $80.70 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.29 | 2019-2025 | Trintellix |
| Biofire Diagnostics, LLC | $75.02 | 2019 | |
| Amarin Pharma, INC. | $71.60 | 2020-2021 | |
| Glaxosmithkline, LLC. | $69.45 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $49.53 | 2021-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $43.22 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $35.57 | 2025 | Ozempic |
| Abbvie INC. | $30.83 | 2025 | |
| Merck Sharp & Dohme LLC | $28.97 | 2025 | Capvaxive, Gardasil 9, Vaxelis |
| Harmony Biosciences LLC | $24.43 | 2025 | |
| Phadia US INC. | $23.82 | 2019 | |
| Ascendis Pharma Endocrinology INC | $21.06 | 2025 | Yorvipath |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $17.38 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.52 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $14.19 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.32 | 2019 | |
| Cranial Technologies, INC | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sterling Ransone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.